المؤلفون: Hana Al-Abdulkarim, Yuvraj Sharma, Suzan M. Attar, Waleed Husain, Ibrahim Al-Homood, Bedor Al Omari, Omneya Mohamed, Mai Alsaqa’aby, Ahmed M. Jaheen, Ali Anwar, Tharwat M. Hamad, Zeyad Alzahrani

مصطلحات موضوعية: Medicine, Pharmacology, Biotechnology, Ecology, Immunology, Science Policy, Costs and cost analysis, cost-effectiveness, incremental cost utility ratio, quality-adjusted life-years, rheumatoid arthritis, adalimumab-originator/ biosimilar, biologic disease modifying anti-rheumatic drug, tofacitinib, upadacitinib, kingdom of saudi arabia, I15, I1, C52, C5

Relation: https://figshare.com/articles/journal_contribution/Cost-effectiveness_analysis_of_upadacitinib_as_a_treatment_option_for_patients_with_rheumatoid_arthritis_in_the_Kingdom_of_Saudi_Arabia/24923772

الاتاحة: https://doi.org/10.6084/m9.figshare.24923772.v1
https://figshare.com/articles/journal_contribution/Cost-effectiveness_analysis_of_upadacitinib_as_a_treatment_option_for_patients_with_rheumatoid_arthritis_in_the_Kingdom_of_Saudi_Arabia/24923772